ST6GAL1 and prostate cancer: Our findings identify ST6GAL1 and sialoglycans as major contributors to prostate cancer bone metastasis and highlight a new opportunity to combine sialic acid blockade with existing anti-androgen and immunotherapy treatments to develop urgently needed new combination therapies for advanced prostate cancer.